Phase 2 N=100 Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy
Acute Pain
Primary: SPID-12 — -5.65; 6.53; -7.12 units on a scale — p=0.742
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=610 A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
Prevention · Venous Thromboembolism
Primary: Incidence of Subjects With Venous Thromboembolism Events — 2.4; 6.9 percentage of subjects with vte events — p=<0.001
Phase 3 N=357 Bimatoprost for the Treatment of Eyebrow Hypotrichosis
Eyebrow Hypotrichosis
Primary: Percentage of Participants With at Least a 1-Grade Increase (Improvement) in the 4-Point Global Eyebrow Assessment (GEBA) Scale — 83.9; 77.1; 43.0 percentage of…
Phase 3 N=492 Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Depression
Primary: Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30) — -18.8; -20.9; -20.7 units on a…
Phase 3 N=93 Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment
Non-valvular Atrial Fibrillation
Primary: Incidence of Any Adjudicated Bleeding Events — 20.0; 22.7; 23.8 percentage of subjects with bleeds
N/A N=20 Floseal Treatment for Posterior Epistaxis Study
Epistaxis
Primary: Effectiveness of Floseal for the Treatment of Posterior Epistaxis. — 20 participants
Phase 3 N=399 Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Depression
Primary: Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30) — -19.4; -20.8 units on a scale…
Phase 4 N=116 Preventing Propofol Injection Pain: Prospective Randomized Trial Comparing Propofol Versus Fospropofol
Complication of Injection · Pain
Primary: Compare Incidence and Intensity of Pain on Injection That is Caused by Propofol (Lipid Emulsion) Versus the Test Drug Fospropofol.
Phase 2 N=112 A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Average Eye Mean Diurnal Intraocular Pressure (IOP) — 24.54; 24.38; 24.29; -6.79 Millimeters of Mercury (mmHg)
Phase 2 N=523 A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
Venous Thromboembolism · Deep Vein Thrombosis · Total Knee Arthroplasty
Primary: Proportion of Subjects With Venous Thromboembolism Events. — 29.5; 26.1; 12.5; 9.1 percentage of participants — p=<0.001
N/A N=50 Value of Mifepristone in Cervical Preparation Prior to Dilation and Evacuation 19-24 Weeks
Abortion, Induced
Primary: Procedure Time — 10.9; 11.8 minutes
N/A N=20 Anterior Capsule Polishing Effect on Effective Lens Position
Cataract
Primary: Effective Lens Position — 3.97; 4.02; 3.93; 3.99 mm
N/A N=511 NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
Atrial Fibrillation · Paroxysmal Arrhythmia
Primary: Total Fluoroscopy Time — 26.4 minutes
Phase 2 N=57 Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer
Ovarian Neoplasm
Primary: Confirmed Objective Tumour Response (According to Response Evaluation Criteria In Solid Tumors (RECIST) — 3; 11; 3; 11 Participants
N/A N=300 Patient and Provider Interventions for Managing Osteoarthritis in Primary Care
Osteoarthritis
Primary: Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) — 48.4; 48.4; 43.5; 41.2 units on a scale — p=0.158